161. Farmers' preferences for result-based schemes for grassland conservation in SloveniaTanja Šumrada, Anže Japelj, Miroslav Verbič, Emil Erjavec, 2022, original scientific article Abstract: Government-funded payments for ecosystem services (PES) have increasingly been used to facilitate transactions between users of environmental services and their providers. In order to improve the link between payments and the service provided, some countries in the EU have promoted result-based schemes (RBS), which remunerate farmers for ecological results, as part of their agricultural policy. Since PES programs are voluntary, it is important to understand farmers’ responses before more large-scale implementations of RBS are initiated. Using a choice experiment and a mixed logit model, we elicited the preferences of farmers in two Natura 2000 sites in Slovenia for different design elements of a hypothetical scheme for dry grassland conservation. We found that the majority of farmers preferred the result-based approach over the management-based scheme both in terms of payment conditions and monitoring; one group of farmers preferred the RBS very strongly (average WTA of more than 500 EUR/ha/yr) and another group less strongly (average WTA about 200 EUR/ha/yr). Farmers also showed a higher preference for on-farm advise and training in small groups than for lectures, which would be offered to a larger audience. A collective bonus, which would incentivise coordination and could potentially increase participation rates in the scheme, significantly influenced the farmers’ willingness to adopt the scheme. However, the estimated average WTA was comparable or lower than the 40 EUR/ha annual bonus payment. Older farmers and those who managed small and semi-subsistent farms were significantly more likely to be highly resistant to scheme adoption no matter its design.
Keywords: agrarna politika, kmetijstvo, subvencije, ekosistemske storitve, plačilo za ekosistemske storitve, agricultural policy, agriculture, subsidies, payments for ecosystem services, abiodiversity conservation
Published in DiRROS: 04.02.2022; Views: 903; Downloads: 681
 Full text (2,14 MB)
This document has many files! More... |
162. |
163. Priporočila Onkološkega inštituta za zdravljenje bolnikov z adenokarcinomom želodcaErik Brecelj, Vesna Zadnik, Neva Volk, Mateja Krajc, Ana Blatnik, Ksenija Strojnik, Nina Boc, Yasmin Marianna Hunt, Gorana Gašljević, Jera Jeruc, Srdjan Novaković, Marko Boc, Franc Anderluh, Martina Reberšek, Borut Štabuc, Irena Oblak, Janja Ocvirk, Ana Jeromen, Zvezdana Hlebanja, Tanja Mesti, Marija Ignjatović, Nežka Hribernik, Ibrahim Edhemović, Gašper Pilko, Rok Petrič, Ajra Šečerov Ermenc, Nada Rotovnik-Kozjek, Vaneja Velenik, Sonja Kramer, Maja Ebert Moltara, Jernej Benedik, 2021, professional article Keywords: adenokarcinom želodca, priporočila, prebavni trakt, multidisciplinarno zdravljenje
Published in DiRROS: 16.12.2021; Views: 1208; Downloads: 537
Full text (355,48 KB)
This document has many files! More... |
164. |
165. Infiltration processes in karst aquifers affected by large-scale forest disturbancesUrša Vilhar, Mitja Ferlan, Janez Kermavnar, Erika Kozamernik, Aleksander Marinšek, Metka Petrič, Tanja Pipan, Daniel Žlindra, Nataša Ravbar, 2021, published scientific conference contribution abstract Keywords: karst hydrogeology, global environmental changes, large-scale forest disturbances, aquifer recharge, water monitoring
Published in DiRROS: 03.12.2021; Views: 1169; Downloads: 716
Full text (277,79 KB)
This document has many files! More... |
166. |
167. Priročnik za določanje korenin olesenelih rastlinTanja Mrak, Jožica Gričar, Peter Železnik, Hojka Kraigher, 2016, published scientific conference contribution abstract Keywords: določevalni ključi, znanstvene monografije, morfologija rastlin, anatomija rastlin, drobne korenine, EUFORINNO
Published in DiRROS: 03.11.2021; Views: 773; Downloads: 0 |
168. Ectomycorrhiza between Scleroderma Areolatum Ehrenb. and Fagus sylvatica L.Tanja Mrak, Katja Kühdorf, Tine Grebenc, Ines Štraus, Marko Bajc, Nada Žnidaršič, Babette Münzenberger, Hojka Kraigher, 2015, published scientific conference contribution abstract Published in DiRROS: 03.11.2021; Views: 874; Downloads: 281
Full text (1,05 MB) |
169. |
170. Immunotherapy for metastatic non-small cell lung cancer : real-world data from an academic Central and Eastern European centerMarija Ivanović, Lea Knez, Ana Herzog, Mile Kovačević, Tanja Čufer, 2021, original scientific article Abstract: Background. Immunotherapy with immune checkpoint inhibitors (ICIs) recently became the standard treatment for patients with advanced non-small cell lung cancer (NSCLC). Here, we present the first results of a real-world observational study on the effectiveness of ICI monotherapy in patients with advanced NSCLC treated at a single academic center in a Central and Eastern European (CEE) country. Materials and methods. Overall, 66 consecutive patients with advanced NSCLC treated with ICIs in everyday clinical practice, either with first-line pembrolizumab (26 patients) or second-line atezolizumab, nivolumab, or pembrolizumab (40 patients), from August 2015 to November 2018, were included. All data were retrieved from a hospital lung cancer registry, in which the data is collected prospectively. Results. Included patients had a median age of 64 years, most were male (55%), 6% were in performance status >/=2, and 18% had controlled central nervous system metastases at baseline. In first-line, the median progression-free survival (mPFS) was 9.3 months, while the median overall survival (mOS) was not reached. The 1-year overall survival (OS) was 62%. In second-line, the mPFS and mOS were 3.5 months and 9.9 months, respectively, with a 1-year OS of 35%. In the overall population, adverse events of any grade were recorded in 79% of patients and of severe grade (3-4) in 12% of patients. Conclusion. The first real-world outcomes of NSCLC immunotherapy from a CEE country suggest comparable effectiveness to those observed in clinical trials and other real-world series, mainly coming from North America and Western European countries. Further data to inform on the real-world effectiveness of immunotherapy worldwide are needed.
Keywords: non-small cell lung carcinoma, immunotherapy, advanced non-small cell lung cancer, real-world data, Central Europe, Europe, Eastern Europe
Published in DiRROS: 12.10.2021; Views: 979; Downloads: 303
 Link to file |
